BEREN THERAPEUTICS
Beren Therapeutics is a biotechnology company that develops innovative therapies to make them accessible to every patient. The company was founded in 2020 and is based in Bonn, Germany.
BEREN THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2020-01-01
Address:
Bonn, Nordrhein-Westfalen, Germany
Country:
Germany
Status:
Active
Similar Organizations
Albireo Pharma
Albireo Pharma a biotechnology company develops therapeutic drugs for gastrointestinal diseases.
Arktis Radiation Detectors
Arktis Radiation Detectors has developed a platform technology for detecting ionizing radiation using compressed noble gas.
Onward
Onward develops an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Marinomed
Marinomed is a biopharmaceutical company that develops innovative anti-viral and immunological treatments.
MitoRx Therapeutics
MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction.
VIVAN Therapeutics
VIVAN Therapeutics is a company pioneering personalized cancer therapeutics using a new assay technology.
Outrun TX
Outrun TX develops a platform for the identification of therapeutics that selectively target the protein degradation pathway.
SynaptixBio
SynaptixBio is a biotechnology research company that develops lifesaving therapies for severe leukodystrophies.
Tally Health
Tally Health™ is a biotechnology company founded to change the way we age. Co-founded by longevity expert Dr. David Sinclair.
More informations about "Beren Therapeutics"
Beren Therapeutics - PitchBook
Beren Therapeutics was founded in 2020. Where is Beren Therapeutics headquartered? Beren Therapeutics is headquartered in Bonn, Germany. What industry is Beren Therapeutics in? Beren Therapeutics’s primary industry is …See details»
Innovation Agreement Roquette - Beren Therapeutics …
May 23, 2023 La Madeleine, France, and Thousand Oaks, CA, USA - May 23, 2023 – Roquette, a leading provider of pharmaceutical excipients and global leader in plant-based ingredients, is pleased to announce a strategic …See details»
Beren Therapeutics - VentureRadar
Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and …See details»
Beren Therapeutics - Crunchbase
Beren Therapeutics, Juventas Therapeutics, Marinomed, UVLrx Therapeutics, Amylon Therapeutics, and GamaMabs Pharma operate in the biotechnology and pharmaceutical …See details»
Roquette Announces Strategic Investment and …
May 23, 2023 Beren media contact Beren Patient and Community Engagement Cathy Traz [email protected] Roquette media contacts Roquette Global Pharmaceutical Business Communication Emily Delommez emily.delommez ...See details»
Beren Awarded Expedited Roadmap for Treatment of …
Nov 17, 2022 Beren Therapeutics, P.B.C. (Beren), a biotechnology company, today announced that its novel lead asset, BRN-002, was awarded an Innovation Passport unSee details»
Roquette Announces Investment and Innovation …
May 23, 2023 Roquette, a provider of pharmaceutical excipients and plant-based ingredients announced a strategic investment with Beren Therapeutics P.B.C., and the launch of an innovation agreement to expand the full potential …See details»
Roquette Announces Strategic Investment and …
May 23, 2023 Roquette, a leading provider of pharmaceutical excipients and global leader in plant-based ingredients, is pleased to announce a strategic investment with Beren Therapeutics P.B.C., and the launch of an innovation …See details»
Roquette Announces Strategic Investment and Innovation
May 23, 2023 LA MADELEINE, France & THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Roquette, a leading provider of pharmaceutical excipients and global leader in plant-based …See details»
Roquette announces strategic investment and …
May 26, 2023 Roquette, a leading provider of pharmaceutical excipients and global leader in plant-based ingredients, announced a strategic investment with Beren Therapeutics and the launch of an innovation agreement to expand the …See details»
BEREN THERAPEUTICS - Roquette
May 22, 2023 BEREN THERAPEUTICS PUBLIC PRESS RELEASE Roquette Announces Strategic Investment and Innovation Agreement with Beren Therapeutics P.B.C. La …See details»
Hydroxypropyl betadex - Beren Therapeutics - AdisInsight - Springer
Nov 22, 2022 15 Feb 2022 Beren Therapeutics plans a phase I trial for Atherosclerosis (In Volunteers) in New Zealand (IV) (ACTRN12622000198729) ... If your organization or you do …See details»
Beren Awarded Expedited Roadmap for Treatment of …
Nov 17, 2022 By: Beren Therapeutics, P.B.C. via Business Wire November 17, 2022 at 09:00 AM EST Beren Therapeutics, P.B.C. (Beren), a biotechnology company, today announced that …See details»
Roquette enters strategic investment and innovation arrangement …
Thousand Oaks, California - Global leader in plant-based ingredients, Roquette, is excited to announce a strategic investment in Beren Therapeutics P.B.C. This partnership also involves …See details»
Roquette Announces Strategic Investment and Innovation …
23 May 2023 -- La Madeleine, France, and California, US -- Roquette, a leading provider of pharmaceutical excipients and global leader in plant-based ingredients, is pleased to …See details»
Roquette, Beren Therapeutics join forces to advance cyclodextrin ...
Roquette, a leading provider of pharmaceutical excipients and global leader in plant-based ingredients, is pleased to announce a strategic investment with Beren Therapeutics P.B.C., …See details»
Estimating the Benefits of Combination Medical Therapy in Heart …
May 23, 2022 Dr Claggett reports consultancy fees from Amgen Inc, Beren Therapeutics, Myokardia, Novartis, and Peerbridge Health. Dr Fonarow reports receiving research funding …See details»
Beren Awarded Expedited Roadmap for Treatment of …
Nov 18, 2022 WEST HOLLYWOOD, Calif.–(BUSINESS WIRE)–Beren Therapeutics, P.B.C. (Beren), a biotechnology company, today announced that its novel lead asset, BRN-002, was …See details»
Bempedoic Acid for Primary Prevention of Cardiovascular Events in ...
A contract research organization collected the data, which were transferred to C5Research at completion of the trial; C5Research statisticians conducted the analyses for this article. ...See details»